Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385593
Status:
TERMINATED
Last Update Posted:
2010-12-16
First Post:
2006-10-06
Brief Title:
Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Comparison of Symbicort Single Inhaler Therapy Symbicort Turbuhaler 16045 Micrograms 1 Inhalation bid Plus as Needed and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-week Randomised Open-label Parallel-group Multicentre Study Study SPAIN
Status:
TERMINATED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigators judgement in patients who present with symptoms on inhaled glucocorticosteroids GCS treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists LABA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SPAIN | None | None | None |
| 2005-005974-64 | None | None | None |